Menu
Search
|

Menu

Close
X

Inflarx NV IFRX.OQ (NASDAQ Stock Exchange Global Select Market)

45.30 USD
-0.86 (-1.86%)
As of 1:46 PM GMT
chart
Previous Close 46.16
Open 46.11
Volume 1,251
3m Avg Volume 18,378
Today’s High 46.11
Today’s Low 45.00
52 Week High 50.52
52 Week Low 20.31
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.62 Mean rating from 8 analysts

KEY STATS

Revenue (mm, EUR)
FY18
0
FY17
0
FY16
0
EPS (EUR)
FY18
-0.777
FY17
-1.003
FY16
-0.520
*Note: Units in Millions of Euro
**Note: Units in Euro

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.54
Price to Sales (TTM)
vs sector
--
8.39
Price to Book (MRQ)
vs sector
--
5.27
Price to Cash Flow (TTM)
vs sector
--
24.12
Total Debt to Equity (MRQ)
vs sector
--
16.02
LT Debt to Equity (MRQ)
vs sector
--
11.35
Return on Investment (TTM)
vs sector
--
13.82
Return on Equity (TTM)
vs sector
--
15.25

EXECUTIVE LEADERSHIP

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Winzerlaer Str. 2
JENA     07745

Phone: +493641.508180

Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.

SPONSORED STORIES